enVVeno Medical Corporation (NASDAQ:NVNO – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 24,103 shares, an increase of 104.8% from the October 15th total of 11,771 shares. Based on an average trading volume of 39,897 shares, the days-to-cover ratio is currently 0.6 days. Approximately 4.1% of the company’s shares are short sold.
enVVeno Medical Stock Performance
Shares of NVNO stock traded down $0.22 during midday trading on Monday, hitting $5.95. 12,092 shares of the company were exchanged, compared to its average volume of 20,942. enVVeno Medical has a 52 week low of $5.80 and a 52 week high of $14.66. The firm has a market capitalization of $4.11 million, a P/E ratio of -0.34 and a beta of 1.41. The firm’s 50 day moving average price is $8.11 and its two-hundred day moving average price is $10.09.
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported ($6.29) earnings per share for the quarter, missing the consensus estimate of ($3.27) by ($3.02). Analysts expect that enVVeno Medical will post -16.19 EPS for the current year.
Analyst Upgrades and Downgrades
Several analysts have commented on NVNO shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of enVVeno Medical in a research report on Friday, September 25th. Wall Street Zen lowered enVVeno Medical from a “hold” rating to a “sell” rating in a research report on Sunday, November 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, enVVeno Medical currently has a consensus rating of “Hold”.
Read Our Latest Research Report on NVNO
About enVVeno Medical
enVVeno Medical is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart. The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition.
Read More
- Five stocks we like better than enVVeno Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
